Direkt zum Inhalt
Merck

Fortfahren mit

G8173

GW833972A

≥98% (HPLC), powder

Synonym(e):

2-[(3-chlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)-5-Pyrimidinecarboxamide hydrochloride

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
5 mg
Warenkorb auf Verfügbarkeit prüfen
€ 199,00
€ 169,15

Über diesen Artikel

Empirische Formel (Hill-System):
C18H13ClF3N5O · HCl
CAS-Nummer:
Molekulargewicht:
444.24
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated

€ 169,15

Listenpreis€ 199,00Sparen Sie 15%
Aktion nur im Web

Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


Quality Level

assay

≥98% (HPLC)

form

powder

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

storage condition

desiccated

color

off-white to light brown

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

Cl.FC(F)(F)c1nc(Nc2cccc(Cl)c2)ncc1C(=O)NCc3ccncc3

InChI

1S/C18H13ClF3N5O.ClH/c19-12-2-1-3-13(8-12)26-17-25-10-14(15(27-17)18(20,21)22)16(28)24-9-11-4-6-23-7-5-11;/h1-8,10H,9H2,(H,24,28)(H,25,26,27);1H

InChI key

UBHSVFAUAKIVKL-UHFFFAOYSA-N

Application

GW833972A, a selective CB2 cannabinoid receptor agonist, may be used separately or in comparison to other cannabinoid receptor agonist and antagonists to differentiate and characterize the CB2 cannabinoid receptor. GW833972A may be used to help verify that an observed physiological response is cannabinoid receptor CB2-dependent.

Biochem/physiol Actions

GW833972A is a CB2 cannabinoid receptor agonist with 1000-fold selectivity relative to CB1.
GW833972A is a CB2 cannabinoid receptor agonist with 1000-fold selectivity relative to CB1. It is, however, 15-fold less potent than HU210 for CB2 (Ki 7.8 vs. 0.52 nM). The antitumor compound oxaliplatin induces marked hypersensitivity to cold, heat, and chemical pain stimuli (to the point where oxaliplatin therapy has to be discontinued). The hyperalgesia effect is almost completely blocked by pretreatment with GW833972A.
GW833972A is a CB2 receptor agonist with 1000-fold selectivity relative to CB1.
The compound was used to determine the role of CB2 in airway sensory nerve function.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
SML0345SML1906SML0988
form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

drug control

-

drug control

-

drug control

-

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥20 mg/mL

solubility

DMSO: ≥5 mg/mL

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear


pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Lagerklasse

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Joanna M Wardlaw et al.
Neurology, 82(15), 1331-1338 (2014-03-14)
To determine the magnitude of potentially causal relationships among vascular risk factors (VRFs), large-artery atheromatous disease (LAD), and cerebral white matter hyperintensities (WMH) in 2 prospective cohorts. We assessed VRFs (history and measured variables), LAD (in carotid, coronary, and leg
Chen Stein-Zamir et al.
The Pediatric infectious disease journal, 33(7), 777-779 (2014-03-14)
We evaluated the outcome of invasive meningococcal disease in children <15 years of age (n = 181). Neisseria meningitidis serogroup B comprised 78% of bacterial isolates. Case fatality rate was 11.6%. In follow-up interviews (115/160 survivors, 72%), at least 1
Michael Mannstadt et al.
The lancet. Diabetes & endocrinology, 1(4), 275-283 (2014-03-14)
Hypoparathyroidism results in impaired mineral homoeostasis, including hypocalcaemia and hyperphosphataemia. Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent control of biochemical indices and can lead to serious long-term complications. We aimed to test



Global Trade Item Number

SKUGTIN
G8173-25MG04061833234556
G8173-5MG04061833643846

Questions

Reviews

No rating value

Active Filters